Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis

Inclusion Criteria

• •Male patients \> 18yrs
• •Osteoporosis prophylaxis/therapy with
• •* vitamin D 800 - 1200 mg per day,
• •* calcium 800 - 1000 mg per day,
• •* Fosamax 70 once a week.
• •Standardised physiotherapy exercise programme.
• •No proliferative bone disease.
• •No history of calcium oxalate stones.
• •No use of aromatase inhibitors.
• •No use of 5-alpha reductase inhibitors.
• •Nebido group:
• •No contraindications to use of Nebido (known prostate or breast carcinoma or suspicion thereof, no past or present history of liver tumours);
• •No known hypersensitivity to testosterone or excipients of Nebido